Instil Bio (TIL) Stock Price, News & Analysis

Company Overview

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $14.34 to $16.32
• 50-Day Range: $14.61 to $26.31
• 52-Week Range: $9.62 to $92.00
• Volume: 140,313 shs
• Average Volume: 117,431 shs
• Market Capitalization: $95.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $114.00
• Consensus Rating: Buy

Instil Bio Stock Analysis - MarketRank™

Instil Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 595th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Instil Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Instil Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Instil Bio are expected to grow in the coming year, from ($13.32) to ($11.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Instil Bio is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Instil Bio is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Instil Bio has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.48% of the float of Instil Bio has been sold short.

Short Interest Ratio / Days to Cover

Instil Bio has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Instil Bio has recently increased by 3.69%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Instil Bio does not currently pay a dividend.

Dividend Growth

Instil Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.48% of the float of Instil Bio has been sold short.

Short Interest Ratio / Days to Cover

Instil Bio has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Instil Bio has recently increased by 3.69%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for TIL on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

2 people have added Instil Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Instil Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

46.50% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TIL Stock Analysis - Frequently Asked Questions

How have TIL shares performed this year?

Instil Bio's stock was trading at $19.09 at the beginning of 2025. Since then, TIL shares have decreased by 23.5% and is now trading at $14.61.
View the best growth stocks for 2025 here.

How were Instil Bio's earnings last quarter?

Instil Bio, Inc. (NASDAQ:TIL) posted its earnings results on Tuesday, March, 4th. The company reported ($1.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.75) by $1.93.

When did Instil Bio's stock split?

Instil Bio's stock reverse split on Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Instil Bio IPO?

Instil Bio (TIL) raised $250 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 13,900,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities acted as the underwriters for the IPO.

How do I buy shares of Instil Bio?

Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Instil Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Instil Bio investors own include Tesla (TSLA), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Taysha Gene Therapies (TSHA), Viking Therapeutics (VKTX), Golden Minerals (AUMN) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 3/04/2025
• Today: 4/04/2025
• Next Earnings (Estimated): 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TIL
• CIK: 1625584
• Web: www.tillcap.com
• Phone: 972-499-3350
• Fax: N/A
• Employees: 410
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $114.00
• High Stock Price Target: $180.00
• Low Stock Price Target: $52.00
• Potential Upside/Downside: +680.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($11.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-156,090,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.44%
• Return on Assets: -25.08%

Debt

• Debt-to-Equity Ratio: 0.47
• Current Ratio: 12.90
• Quick Ratio: 12.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $34.72 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 6,526,000
• Free Float: 3,491,000
• Market Cap: $95.34 million
• Optionable: No Data
• Beta: 1.73